ERIC 2018 | DUO results: duvelisib or ofatumumab monotherapy for R/R CLL?

Stephan Stilgenbauer

The Phase III DUO trial investigated duvelisib vs. ofatumumab for chronic lymphocytic leukemia (CLL) in the relapsed/refractory setting (NCT02004522). Here, Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany, tells us about the final results of the trial, speaking from the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

Share this video